Table 4

Mean QALYs and costs and cost-effectiveness acceptability analysis, UK £’s, 2018–2019 prices

Follow-upControl (61/132, 46%)RDSI (41/131, 31%)
MeanSE95% CIMeanSE95% CI
Baseline to 4-week follow-up0.0440.0020.0400.0470.0520.0030.0460.057
4–12 weeks follow-up0.0880.0040.0800.0950.1040.0050.0930.114
Baseline to 12 weeks follow-up0.1330.0050.1220.1430.1540.0070.1400.169
Baseline to 4-week follow-up£461£134£195£726£784£522£<1£1820
4–12 weeks follow-up£659£176£310£1008£1450£812£<1£3060
Baseline to 12 weeks follow-up£1120£242£639£1600£2234£1320£<1£4851
Bootstrapped estimatesNet QALY or Cost of RDSI vs control95% percentilesProbability RDSI is cost-effective
£0 per QALY gained
£15 000 per QALY gained
£30 000 per QALY gained
Primary analysis (complete cost and QALY data, n=102)
Net QALYs0.0190.001; 0.0370.060.140.23
Net cost£1401−£544; £3347
Sensitivity analysis (available cost and QALY data, indicator for incomplete data, n=147)
Net QALYs0.0150.001; 0.0300.060.130.21
Net cost£1142-£824; £3108
  • QALY, Quality Adjusted Life Years; RDSI, respiratory distress symptom intervention; WTPT, willingness-to-pay threshold.